Diabetes and heart disease are closely linked; studies show that diabetes is frequently combined with other cardiovascular risk factors such as high blood pressure, obesity and lipid disorders, a clustering of risk factors known as metabolic syndrome. Thyroid disorders are closely associated with both diabetes and cardiovascular disease. In patients with type 2 diabetes, thyroid disorders are two to five times more frequent than among the general population. Heart muscle cells contain receptors for thyroid hormones, so cardiac function is influenced by too many or too few thyroid hormones.
Cardiovascular diseases continue to be the most frequent cause of death in industrialized countries. We offer an extensive range of therapeutic options to treat these conditions, along with drugs for the treatment of glucose metabolism and thyroid disorders. Our company is among the leading manufacturers of oral antidiabetic agents for the treatment of type 2 diabetes, formerly referred to as “adult-onset diabetes”.
We have a longstanding commitment to the treatment of thyroid diseases, dating back to 1894 when its first thyroid medicine was launched. Today the company markets Euthyrox® (levothyroxine sodium) and Novothyral® (levothyroxine sodium, liothyronine sodium) for the treatment of hypothyroidism, Thyrozol® (thiamazole) for hyperthyroidism, Jodid™ (potassium iodide) for iodine deficiency (a cause of enlargement of the thyroid gland leading to goiter) and Jodthyrox® (levothyroxine sodium and potassium iodide) for the treatment of goiter.